First isolation of Bartonella bovis from animals in French Guyana, South America  by Saisongkorh, W. et al.
10.1111/j.1469-0691.2008.02198.x
First isolation of Bartonella bovis from animals in French Guyana, South
America
W. Saisongkorh1, L. Barrassi1, B. Davoust2, C.-A. de Broucker3, D. Raoult1 and J.-M. Rolain1
1Universite´ de la Me´diterrane´e, Unite´ des Rickettsies, URMITE CNRS-IRD, UMR, Faculte´ de Me´decine
et de Pharmacie, Marseille, 2Direction Re´gionale du Service de Sante´ des Arme´es de Toulon and
3Direction Interarme´es du Service de Sante´ des Arme´es de la Guyane, France
INTRODUCTION
Bartonella species are intracellular parasites of
erythrocytes and endothelia cells of several ani-
mals, including rodents, ruminants, cats and
dogs, and are considered potential emerging
pathogens in humans. Among ruminants,
B. schoenbuchensis, B. chomelii and B. bovis (for-
merly named B. weissii) have been isolated from
blood in Europe, Africa and North America [1–3].
Although the presence of various Bartonella spe-
cies in animals has been largely studied in these
countries, there are only a few data in South
America. The objective of this study was to detect,
to isolate and to identify the presence of Bartonella




EDTA blood from 27 bovines (Bos taurus), 18 goats (Capra
aegagrus), three felines (Felis catus), one paca (Agouti paca) and
one rat (Rattus spp.) were collected in March 2007 in French
Guyana, South America. The samples were stored at )80C
before analysis. The bacteria were grown onto Columbia base
agar (bioMe´rieux, Marcy l’Etoile, France) at 37C with 5% CO2
and observed for 2 months. Gimenez stain was performed on
the suspected colonies.
DNA ampliﬁcation and sequencing
DNAs of Bartonella isolates were extracted using the QIAamp
DNA Mini Kit (Qiagen, Valencia, CA, USA). The DNA
ampliﬁcation and sequencing was performed using primers
targeting the 16S–23S rRNA intergenic spacer (ITS). Sequences
were compared with those available in the GenBank database
for ﬁnal identiﬁcation.
The quinolone-resistance-determining region (QRDR) of the
gyrase subunitA (gyrA) gene of these isolates was PCR
ampliﬁed and sequenced to look at possible mutations
associated with heterogeneity of susceptibility to ﬂuoroqui-
nolones.
Antimicrobial susceptibility testing
The minimum inhibitory concentrations (MICs) were deter-
mined using Etest assay on Bartonella isolates as in recent
reports [4]. Eleven antibiotics purchased from AB Biodisk
(Solna, Sweden) were tested, including ciproﬂoxacin, oﬂox-
acin, erythromycin, clarithromycin, azithromycin, tetracy-
clines, rifampicin, amoxicillin, ceftriaxone, imipenem and
vancomycin.
RESULTS
Bacterial isolation and molecular identiﬁcation
Among the ﬁve species of animals studied, 19 out
of 27 blood samples from bovines were Bartonella-
positive using blood agar culture after 5–7 days of
incubation whereas none of the other blood
samples were culture positive after a 2-month
observation. The bacterial morphology observed
under a microscope was bacilli by Gimenez
staining.
DNA ampliﬁcation and sequencing of the ITS
gene was positive in these 19 samples, with
sequences having a percentage of similarity
‡98% to that of B. bovis (GenBank accession no.
AY116638). The phylogenetic tree of two of these
isolates belonging to the B. bovis cluster is
depicted in Fig. 1a.
Antimicrobial susceptibility testing
All B. bovis isolates were susceptible to tetracy-
cline (MICs range, 0.016–0.032 mg ⁄mL), rifampi-
cin (MICs range, 0.003–0.006 mg ⁄mL), ß-lactam
(MICs range, 0.016–0.38 mg ⁄mL) and macrolide
compounds (MICs range, 0.016–0.047 mg ⁄mL)
whereas vancomycin was not effective (MICs
range, 24–48 mg ⁄mL).
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We found a heterogeneity of susceptibility to
ﬂuoroquinolones, with ciproﬂoxacin (MICs range,
0.047–0.25 mg ⁄L) being more effective than oﬂox-
acin (MICs range, 0.25–1.0 mg ⁄L). This heteroge-
neity of susceptibility was linked to an intrinsic
mutation Ser-83 Ala (E. coli numbering) in the
QRDR of the gyrA gene (Fig. 1b).
DISCUSSION
To the best of our knowledge, we report the ﬁrst
detection and isolation of B. bovis from bovines in
French Guyana, South America. Although only a
few blood samples were tested in this study, we
found a high prevalence (70%) of bacteraemic
bovines. This high level of infected animals was
also reported in other countries, including France
[1], the USA (2) and Cote d’Ivoire (West Africa)
[3], with prevalence of 36%, 50–89% and 20%,
respectively. Our ﬁndings demonstrate that
B. bovis probably has a worldwide distribution
in cattle, with a high proportion of infected
animals. Only a few numbers of Bartonella species
have been detected or isolated in South America
to date, including B. bacilliformis, the causative
agent of Carrion’s disease in humans, B. rochali-
mae as a causative agent of spenomegaly with
fever in humans, B. henselae, the causative agent of
cat scratch disease in humans, and B. quintana, the
causative agent of trench fever in humans.
(a)
(b)
Fig. 1. Phylogenetic tree of isolates
from the B. bovis cluster.
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Moreover, our data also clearly conﬁrm that all
Bartonella species harboured an intrinsic mutation
in the QRDR of gyrA (Ser-83 Ala), conﬁrming a
low level of resistance to ﬂuoroquinolone, as
recently reported for B. henselae, B. quintana,
B. bacilliformis and B. australis [4], suggesting that
such antibiotics should be avoided in case of
Bartonella infections either in humans or in ani-
mals. Because humans are in close contact with
these domestic animals, B. bovis may be a
potential agent of zoonosis in humans. This was
clearly exempliﬁed with B. rochalimae, ﬁrst de-
tected in a Pulex ﬂea from Peru in 2002 and
recently isolated from a patient with fever and
splenomegaly [5]. More investigations are war-
ranted in order to determine if this species can
cause any clinical manifestations.
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